Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma

Published:2017-06 Issue:6 Volume:28 Page:1352-1358
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bröckelmann P.J.,Müller H.,Casasnovas O.,Hutchings M.,von Tresckow B.,Jürgens M.,McCall S.J.,Morschhauser F.,Fuchs M.,Borchmann P.,Moskowitz C.H.,Engert A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/6/1352/27765928/mdx072.pdf

Reference12 articles.

1. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

2. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma;Josting;J Clin Oncol,2010

3. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leuk Lymphoma,2013

4. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma;Younes;JCO,2012

5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial;Younes;Lancet Oncol,2016

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

2. Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China;Health Economics Review;2024-06-06

3. Aktuelle Standards in der Behandlung des Hodgkin Lymphoms;DMW - Deutsche Medizinische Wochenschrift;2024-05-23

4. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma;Blood Advances;2023-11-02

5. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade;Blood;2023-10-19